Vanguard Capital Management
HRTX icon

Vanguard Capital Management’s Heron Therapeutics HRTX Stock Holding History

Vanguard Capital Management’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.32M Sell
7,782,741
-27,588
-0.4% -$22.1K ﹤0.01% 3254
2026
Q1 		$6.25M Buy
+7,810,329
New +$9.05M ﹤0.01% 2968

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management's HRTX Position: Q2 2026 in Review

Vanguard Capital Management reduced its Heron Therapeutics (HRTX) stake by 0.35% in Q2 2026, selling an estimated $22.1K and leaving 7,782,741 shares worth $3.32M. The position accounts for ﹤0.01% of the portfolio, ranked #3254.

Vanguard Capital Management first reported a position in HRTX in Q1 2026 and has held it in 2 quarters since. The position peaked at $6.25M in Q1 2026. 162 funds tracked by Wall St. Rank hold HRTX as of Q2 2026.

  • Vanguard Capital Management held 7,782,741 shares of Heron Therapeutics worth $3.32M as of Q2 2026.
  • Vanguard Capital Management sold 27,588 Heron Therapeutics shares in Q2 2026, an estimated $22.1K.
  • Heron Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3254 holding.
  • Vanguard Capital Management first reported a position in Heron Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Capital Management's Heron Therapeutics position peaked at $6.25M in Q1 2026.
  • 162 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.